<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        49-51-08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2008
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TOPAMAX 25MG SPRINKLE CAPSULES
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TOPIRAMATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        41.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="JANSSEN - ORTHO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            JANSSEN - ORTHO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            JANSSEN - ORTHO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX11
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Topamax belongs to a group of medicines called &ldquo;anti-epileptic medicines&rdquo;. It is used:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alone to treat seizures in adults and children over age 6</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with other medicines to treat seizures in adults and children aged 2 years and above - &nbsp;&nbsp; to prevent migraine headaches in adults</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Topamax</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to topiramate or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for migraine prevention if you are pregnant or you are able to become pregnant but you are not using effective contraception (see section &lsquo;pregnancy and breastfeeding&rsquo; for further information).</p><p>&nbsp;</p><p>If you are not sure if the above applies to you, talk to your doctor or pharmacist before using Topamax.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>&nbsp;</p><p>Talk to your doctor or pharmacist before taking Topamax if you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney problems, especially kidney stones, or are getting kidney dialysis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a history of blood and body fluid abnormality (metabolic acidosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have liver problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have eye problems, especially glaucoma</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a growth problem</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are on a high fat diet (ketogenic diet)</p><p>are pregnant or could become pregnant (see section &lsquo;pregnancy and breastfeeding&rsquo; for further information)</p><p>&nbsp;</p><p>If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before using Topamax.</p><p>&nbsp;</p><p>It is important that you do not stop taking your medicine without first consulting your doctor.</p><p>&nbsp;</p><p>You should also talk to your doctor before taking any medicine containing topiramate that is given to you as an alternative to Topamax.</p><p>&nbsp;</p><p>You may lose weight if you use Topamaxso your weight should be checked regularly when using this medicine. If you are losing too much weight or a child using this medicine is not gaining enough weight, you should consult your doctor.</p><p>&nbsp;</p><p>A small number of people being treated with anti-epileptic medicines such as Topamaxhave had thoughts of harming or killing themselves. If at any time you have these thoughts, immediately contact your doctor.</p><p>&nbsp;</p><p>Other medicines and Topamax</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Topamaxand certain other medicines can affect each other. Sometimes the dose of some of your other medicines or Topamax will have to be adjusted.</p><p>&nbsp;</p><p>Especially, tell your doctor or pharmacist if you are taking:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines that impair or decrease your thinking, concentration, or muscle coordination (e.g. central nervous system depressant medicines such as muscle relaxants and sedatives).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; birth control pills. Topamaxmay make your birth control pills less effective.</p><p>&nbsp;</p><p>Tell your doctor if your menstrual bleeding changes while you are taking birth control pills and Topamax.</p><p>&nbsp;</p><p>Keep a list of all the medicines you take. Show this list to your doctor and pharmacist before you start a new medicine.</p><p>&nbsp;</p><p>Other medicines you should discuss with your doctor or pharmacist include other anti-epileptic medicines, risperidone, lithium, hydrochlorothiazide, metformin, pioglitazone, glyburide, amitriptyline, propranolol, diltiazem, venlafaxine, flunarazine, St. John&#39;s wort (<em>Hypericum perforatum</em>) (a herbal preparation used to treat depression).</p><p>&nbsp;</p><p>If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before using Topamax.</p><p>&nbsp;</p><p>Topamax with food and drink</p><p>&nbsp;</p><p>You can take Topamax with or without food. Drink plenty of fluids during the day to prevent kidney stones while taking Topamax. You should avoid drinking alcohol when taking Topamax.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>Your doctor will discuss use of contraceptives with you, as well as discussing whether Topamax is suitable for you. As with other anti-epileptic medicines, there is a risk of harm to the unborn child if Topamax is used during pregnancy. Make sure you are very clear about the risks and the benefits of using Topamaxfor epilepsy during pregnancy.</p><p>&nbsp;</p><p>You should not take Topamax for migraine prevention if you are pregnant or you are able to become pregnant and you are not using effective contraception.</p><p>&nbsp;</p><p>Mothers who breast-feed while taking Topamax must tell the doctor as soon as possible if the baby experiences anything unusual.<strong> </strong></p><p>&nbsp;</p><p>&nbsp;</p><p>Driving and using machines</p><p>&nbsp;</p><p>Dizziness, tiredness, and vision problems may occur during treatment with Topamax. Do not drive or use any tools or machines without talking to your doctor first.</p><p>&nbsp;</p><p>Topamax contains sucrose</p><p>&nbsp;</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will usually start you on a low dose of Topamax and slowly increase your dose until the best dose is found for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Topamax sprinkle capsules may be swallowed whole or may be opened and sprinkled on a teaspoon of soft food of any type. Examples are applesauce, custard, ice cream, porridge, pudding or yogurt. Drink fluids right after to make sure all of the food and medicine mixture is swallowed.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the sprinkle capsule upright so that you can read the word &ldquo;TOP.&rdquo;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carefully twist off the clear portion of the capsule. You may find it best to do this over the small portion of food onto which you will be pouring the sprinkles.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sprinkle all of the capsule&rsquo;s contents onto a spoonful of soft food, taking care to see that the entire prescribed dosage is sprinkled onto the food.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Be sure to swallow the entire spoonful of the sprinkle/food mixture immediately. Avoid chewing. Drink fluids immediately in order to make sure all of the mixture is swallowed.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Never store any medicine and food mixture for use at a later time.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Topamax can be taken before, during, or after a meal. Drink plenty of fluids during the day to prevent kidney stones while taking Topamax.</p><p>&nbsp;</p><p>If you take more Topamaxthan you should</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See a doctor right away. Take the medicine pack with you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may feel sleepy, tired, or less alert; lack coordination; have difficulty speaking or concentrating; have double or blurred vision; feel dizzy due to low blood pressure; feel depressed or agitated; or have abdominal pain, or seizures (fits).</p><p>&nbsp;</p><p>Overdose can happen if you are taking other medicines together with Topamax.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>If you forget to take Topamax</p><p>&nbsp;</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget to take a dose, take it as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose and continue as usual. If you miss two or more doses, contact your doctor.</p><p>Do not take a double dose (two doses at the same time) to make up for a forgotten dose.</p><p>&nbsp;</p><p>If you stop taking Topamax</p><p>&nbsp;</p><p>Do not stop taking this medicine unless told to do so by your doctor. Your symptoms may return. If your doctor decides to stop this medication, your dose may be decreased gradually over a few days.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Tell your doctor, or seek medical attention immediately if you have the following side effects: </strong></p><p>Very common (may affect more than 1 in 10 people) Common (may affect up to 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression (new or worse)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures (fits)&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety, irritability, changes in mood, confusion, disorientation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with concentration, slowness of thinking, loss of memory, problems with memory (new onset, sudden change or increased severity)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney stone, frequent or painful urination</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased acid level in the blood (may cause troubled breathing including shortness of breath, loss of appetite, nausea, vomiting, excessive tiredness, and fast or uneven heart beats)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased or loss of sweating (particularly in young children who are exposed to high temperatures)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Having thoughts of serious self-harm, trying to cause serious self-harm</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of part of the field of vision</p><p>Rare (may affect up to 1 in 1,000 people)</p><p>- Glaucoma &ndash; blockage of fluid in eye causing increased pressure in the eye, pain, or decreased vision</p><p>&nbsp;</p><p><strong>Other side effects include the following, if they get serious, please tell your doctor or pharmacist: </strong></p><p>&nbsp;</p><p>Very common (may affect more than 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stuffy, runny nose or sore throat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tingling, pain and/or numbness of various body parts</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleepiness, tiredness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea, diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight loss</p><p><strong>&nbsp;</strong></p><p>Common (may affect up to 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia (low blood count)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction (such as skin rash, redness, itching, facial swelling, hives)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite, decreased appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aggression, agitation, anger, abnormal behaviour</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty falling or staying asleep</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with speech or speech disorder, slurred speech</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clumsiness or lack of coordination, feeling of unsteadiness when walking&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased ability to complete routine tasks</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased, loss of, or no sense of taste</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Involuntary trembling or shaking; rapid, uncontrollable movements of the eyes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visual disturbance, such as double vision, blurred vision, decreased vision, difficulty focusing - &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensation of spinning (vertigo), ringing in the ears, ear pain</p><p>&nbsp;</p><p>Shortness of breath</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nose bleeds</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever, not feeling well, weakness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting, constipation, abdominal pain or discomfort, indigestion, stomach or intestinal infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain or swelling, muscle spasms or twitching, muscle aches or weakness, chest pain - &nbsp;&nbsp;&nbsp;&nbsp; Weight gain</p><p>&nbsp;</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in platelets (blood cells that help stop bleeding), decrease in white blood cells that help to protect you against infection, decrease in potassium level in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in liver enzymes, increase in eosinophils (a type of white blood cell) in the blood - &nbsp;&nbsp; Swollen glands in the neck, armpit, or groin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated mood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hearing, seeing, or feeling things that are not there, severe mental disorder (psychosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Showing and/or feeling no emotion, unusual suspiciousness, panic attack</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with reading, speech disorder, problems with handwriting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restlessness, hyperactivity</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slowed thinking, decreased wakefulness or alertness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced or slow body movements, involuntary abnormal or repetitive muscle movements</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal sense of touch; impaired sense of touch</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impaired, distorted, or no sense of smell</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unusual feeling or sensation that may precede a migraine or a certain type of seizure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry eye, sensitivity of the eyes to light, eyelid twitching, watery eyes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased or loss of hearing, loss of hearing in one ear</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow or irregular heartbeat, feeling your heart beating in your chest</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure, low blood pressure upon standing (consequently, some people taking Topamaxmay feel faint, dizzy, or may pass out when they stand up or sit up suddenly)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushing, feeling warm</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pancreatitis (inflammation of the pancreas)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive passing of gas or wind, heartburn, abdominal fullness or bloating</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding gums, increased saliva, drooling, breath odour</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive intake of fluids, thirst</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin discolouration</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle stiffness, pain in side</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood in urine, incontinence (lack of control) of urine, urgent desire to urinate, flank or kidney pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty getting or keeping an erection, sexual dysfunction</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu-like symptoms</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cold fingers and toes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling drunk</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Learning disability</p><p><strong>&nbsp;</strong></p><p>Rare (may affect up to 1 in 1,000 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormally elevated mood&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of consciousness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blindness in one eye, temporary blindness, night blindness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lazy eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling in and around the eyes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numbness, tingling and colour change (white, blue then red) in fingers and toes when exposed to the cold</p><p>Inflammation of the liver, liver failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stevens Johnson syndrome, a potentially life-threatening condition that may present with sores in multiple mucosal sites (such as the mouth, nose, and eyes), a skin rash, and blistering</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal skin odour</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discomfort in your arms or legs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney disorder</p><p>&nbsp;</p><p>Not known (frequency cannot be estimated from the available data)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maculopathy is a disease of the macula, the small spot in the retina where vision is keenest. You should call your doctor if you notice a change or decrease in your vision.&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toxic epidermal necrosis, a life-threatening condition related to, yet more severe than, StevensJohnson syndrome, characterized by widespread blistering and sloughing of the outer layers of the skin (see rare side effects)</p><p>&nbsp;</p><p>Children</p><p><strong>&nbsp;</strong></p><p>The side effects in children are generally similar to those seen in adults, but the following side effects may be more common in children than adults:&nbsp;</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with concentration</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased acid level in the blood&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Having thoughts of serious self-harm&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredeness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased or increased appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aggression, abnormal behaviour</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty falling or staying asleep</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling of unsteadiness when walking</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not feeling well</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in potassium level in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Showing and/or feeling no emotion</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Watery eyes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow or irregular heartbeat</p><p>&nbsp;</p><p>Other side effects that may occur in children are:</p><p>&nbsp;</p><p>Common (may affect up to 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensation of spinning (vertigo)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>&nbsp;</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in eosinophils (a type of white blood cell) in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperactivity - &nbsp;&nbsp; Feeling warm</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Learning disability</p><p>&nbsp;</p><p>Reporting of side effects</p><p><strong>&nbsp;</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>To Report any side effect (s) : </strong></p><p><strong>&nbsp;</strong></p><p>&bull; Saudi Arabia<em> </em></p><p><em>&nbsp;</em></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong><sup>&nbsp;</sup></strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong>o Fax: +966-11-205-7662 &nbsp;o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>&bull; o Toll free phone: 8002490000 <strong><em>Other GCC States: </em></strong></p><p><strong>&nbsp;</strong>o E-mail: <u>npc.drug@sfda.gov.sa</u> <strong><sup>&nbsp;</sup></strong>o Website: www.sfda.gov.sa/npc</p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&bull; &nbsp;&nbsp;&nbsp; <strong>Other GCC states : </strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong>&minus; Please contact the relevant competent authority.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the bottle/carton. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 25&deg;C. Keep the bottle tightly closed to protect the capsules from moisture.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Topamax contains</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is topiramate.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each Topamax sprinkle capsule contains 15, 25, or 50 mg of topiramate.</p><p>&nbsp;</p><p>The other ingredients of Topamaxare listed below:</p><p>Sugar spheres (maize starch, sucrose), povidone, cellulose acetate.</p><p>&nbsp;</p><p><u>Capsule</u></p><p>Gelatine, titanium dioxide (E171)</p><p>&nbsp;</p><p><u>Printing ink</u></p><p>Black ink (iron oxide black (E172), shellac and propylene glycol).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Topamax looks like and contents of the pack 
15 mg capsules: Small white to off-white spheres in sprinkle gelatine capsules with white opaque body marked ‘15 mg’ and clear cap marked 'TOP'. 
25 mg capsules: Small white to off-white spheres in sprinkle gelatine capsules with white opaque body marked ‘25 mg’ and clear cap marked 'TOP'. 
50 mg capsules: Small white to off-white spheres in sprinkle gelatine capsules with white opaque body marked ‘50 mg’ and clear cap marked 'TOP'. 
 
Opaque plastic bottle of HDPE with tamper-evident closure containing 20, 28, 60 or 100 capsules with granules. 
Not all pack sizes may be marketed. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer </strong></p><p>See outer carton&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                28 October 2015 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي توباماكس إلى مجموعة أدوية تسمى &quot;الأدوية المضادة للصرع&quot;. استعمالاته:</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُسُتخدم وحده لعلاج&nbsp; نوبات الصرع لدى البالغين والأطفال في عمر 6 سنوات فأكثر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُسُتخدم مع أدوية أخرى لعلاج التشنجات لدى البالغين والأطفال في عمر سنتين فأكثر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُسُتخدم لمنع الصداع النصفي لدى البالغين</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال توباماكس </strong></p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه التوبيراميت أو أي من المكونات الأخرى في هذا الدواء (مدرجة في القسم 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لمنع الصداع النصفي إذا كنتِ حاملا أو قادرة على الحمل ولكنك لا تستخدمين وسيلة فعالة لمنع الحمل (انظري قسم &quot;الحمل</p><p dir="RTL">والرضاعة الطبيعية&quot; لمزيد من المعلومات.)</p><p>&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا من أن ما ذكر أعلاه ينطبق على حالتك، فاستشر طبيبك أو الصيدلي قبل استخدام دواء توباماكس.</p><p>&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات </strong></p><p>&nbsp;</p><p dir="RTL">استشر طبيبك أو الصيدلي قبل تناول توباماكس إذا كنت تعاني مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الكلى، ولا سيما حصى الكلى أو الغسيل الكلوي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل في الدم وسوائل الجسم (الحماض الأيضي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في العين، ولا سيما المياه الزرقاء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة في النمو</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتبع نظام غذائي مرتفع الدهن (نظام غذائي مولد للكيتون)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ حاملا أو قادرة على الحمل (انظري قسم &quot;الحمل والرضاعة الطبيعية&quot; لمزيد من المعلومات)</p><p>&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا من أن أياًّ مما ذُكِرَ أعلاه ينطبق على حالتك، فاستشر طبيبك أو الصيدلي قبل استخدام دواء توباماكس.</p><p>&nbsp;</p><p dir="RTL">من المهم ألا تتوقف عن تناول الدواء دون استشارة طبيبك أولاً.</p><p>&nbsp;</p><p dir="RTL">ينبغي أيضًا أن تستشر طبيبك قبل تناول أي دواء يحتوي على التوبيراميت الذي وُصف لك كبديل لدواء توباماكس.</p><p>&nbsp;</p><p dir="RTL">قد يظهر عليك خسارة في الوزن إذا كنت تستخدم توباماكس، فيُنُصح بفحص وزنك بانتظام عند استخدام هذا الدواء. إذا ظهرت عليك خسارة كبيرة في الوزن أو إذا لم يصل طفل يستخدم هذا الدواء إلى الوزن الكافي، فيُنُصح باستشارة الطبيب.</p><p>&nbsp;</p><p dir="RTL">راود عددًا صغيرًا ممن يُعُالجون بالأدوية المضادة للصرع مثل توباماكس أفكار بإلحاق الأذى بالنفس أو قتلها. إذا راودتك هذه الأفكار في أي وقت، فاتصل بطبيبك على الفور.</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وتوباماكس</strong></p><p>&nbsp;</p><p dir="RTL">يُرُجى إبلاغ طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">يمكن أن يؤثر توباماكس وبعض الأدوية الأخرى على بعضهم. قد يلزم تغيير جرعة بعض الأدوية الأخرى أو توباماكس في بعض الأحيان.</p><p>&nbsp;</p><p dir="RTL">احرص على أن تبلغ طبيبك أو الصيدلي إذا كنت تتناول:</p><p>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى تضُعف من تفكيرك أو تركيزك أو التناسق العضلي أو تقُلل منهم (مثل أدوية تثبيط الجهاز العصبي المركزي مثل مُرخيات العضلات والمهدئات).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حبوب منع الحمل. قد يجعل توباماكس حبوب منع العمل أقل فعالية.</p><p>&nbsp;</p><p dir="RTL">أبلغي طبيبك إذا تغيرت الدورة الشهرية أثناء تناول حبوب منع الحمل وتوباماكس.</p><p>&nbsp;</p><p dir="RTL">احتفظ بجميع الأدوية التي تتناولها. أطلع طبيبك والصيدلي على هذه القائمة قبل بدء تناول دواء جديد.</p><p>&nbsp;</p><p dir="RTL">تشمل الأدوية الأخرى التي يُنُصح بمناقشتها مع طبيبك أو الصيدلي الأدوية الأخرى المضادة للصرع والريسبيريدون والليثيوم والهيدروكلوروثيازيد والميتفورمين وبيوجليتازوني والغليبوريد والأميتريبتيلين والبروبرانولول والديلتيازيم والفينلافاكسين</p><p dir="RTL">والفلوناريزين ونبتة سانت جون( البيرفوراتوم) (مُستحضر عشبي لعلاج الاكتئاب.)</p><p>&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا من أن أياًّ مما ذُكِرَ أعلاه ينطبق على حالتك، فاستشر طبيبك أو الصيدلي قبل استخدام دواء توباماكس.</p><p>&nbsp;</p><p dir="RTL"><strong>تناول توباماكس مع الطعام والشراب </strong></p><p>&nbsp;</p><p dir="RTL">يمكنك تناول توباماكس مع الطعام أو بدونه. يُفُضل تناول كمية كبيرة من السوائل أثناء اليوم لمنع حصى الكلى أثناء تناول توباماكس .</p><p dir="RTL">ينبغي تجنب شرب الكحول عند تناول توباماكس.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية </strong></p><p>&nbsp;</p><p dir="RTL">إذا كنتِ حاملاً أو ترضعين، أو تعتقدين بأنكِ قد تكونين حاملاً أو تخططين لإنجاب طفل، فاستشيري طبيبكِ للحصول على النصيحة قبل تناول هذا الدواء.</p><p dir="RTL">سيوضح لكِ طبيبك استخدام وسائل منع الحمل وهل توباماكس مناسب لك. كما هو الحال مع الأدوية الأخرى المضادة للصرع، توجد خطورة على الطفل الذي لم يولد بعد إذا تم استخدام توباماكس أثناء الحمل. تأكد من أنك على دراية تامة بمخاطر وفوائد استخدام توباماكس لعلاج الصرع أثناء الحمل.</p><p>&nbsp;</p><p dir="RTL">لا يُنُصح بتناول توباماكس لمنع الصداع النصفي إذا كنتِ حاملاً أو قادرة على الحمل ولا تستخدمين وسيلة فعالة لمنع الحمل.</p><p>&nbsp;</p><p dir="RTL">يجب أن تخبر الأمهات المرضعات أثناء تناول توباماكس الطبيب في أقرب وقت ممكن إذا ظهر على الطفل أي شيء غير عادي.<strong> </strong></p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p>&nbsp;</p><p dir="RTL">قد تحدث دوخة أو إعياء أو مشكلات في الرؤية أثناء العلاج بدواء توباماكس. تجنب القيادة أو استخدام أي أدوات أو أجهزة دون استشارة طبيبك أولاً.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي توباماكس على السكروز </strong></p><p>&nbsp;</p><p dir="RTL">إذا أخبرك طبيبك بأنك تعاني من حساسية مفرطة تجاه بعض السكريات، فاتصل به قبل تناول هذا المنتج الدوائي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائمًا كما أخبرك الطبيب تمامًا. راجع الطبيب أو الصيدلي إذا لم تكن متأكدًا.</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يبدأ الطبيب العلاج عادة بجرعة منخفضة من توباماكس ثم يزيدها ببطء حتى يصل إلى أفضل جرعة تناسبك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن ابتلاع كبسولات توباماكس الللنثر بالكامل أو فتحها ووضعها على ملعقة صغيرة من أي نوع من الطعام الناعم سهل المضغ. مثل عصير التفاح أو الكاسترد أو الآيس كريم أو العصيدة أو الحلوى أو الزبادي. تناول السوائل بعد ذلك مباشرة للتأكد من ابتلاع مزيج الطعام والدواء تمامًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; امسك الكبسولة الللنثر بحيث يكون اتجاهها لأعلى وتستطيع قراءة كلمة&quot; TOP&quot;.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; افتح الجزء الواضح من الكبسولة. قد تجد أنه من الأفضل أن تفعل ذلك على جزء صغير من الطعام الذي ستضع عليه محتويات الكبسولة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع جميع محتويات الكبسولة على ملعقة صغيرة على نوع من الطعام الناعم سهل المضغ وتأكد من أن الجرعة الموصوفة وُضعت بالكامل على الطعام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احرص على ابتلاع ملعقة كاملة من مزيج الطعام/محتويات الكبسولة على الفور. تجنب المضغ. تناول السوائل على الفور للتأكد من ابتلاع المزيج تمامًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تحتفظ بأي مزيج من الدواء والطعام لاستخدامه فيما بعد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن تناول توباماكس قبل الوجبة أو أثناءها أو بعدها. يُفُضل تناول كمية كبيرة من السوائل أثناء اليوم لمنع حصى الكلى أثناء</p><p dir="RTL">تناول توباماكس.</p><p>&nbsp;</p><p dir="RTL"><strong>في حالة تناول توباماكس أكثر مما ينبغي </strong></p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استشر طبيباً في الحال. خذ معك علبة الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشعر بالنعاس أو الإعياء أو درجة يقظة قليلة أو غياب التنسيق أو صعوبة في التحدث أو التركيز أو ازدواج الرؤية أو</p><p dir="RTL">تشوشها أو الدوار بسبب انخفاض ضغط الدم أو الاكتئاب أو الهياج أو ألم في البطن أو تشنجات (نوبات.)</p><p>&nbsp;</p><p dir="RTL">يمكن أن تحدث جرعة زائدة إذا تناولت أدوية أخرى مع توباماكس.</p><p>&nbsp;</p><p dir="RTL"><strong>في حالة نسيان تناول توباماكس </strong></p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة نسيانك تناول الجرعة، تناولها فور تذكرها. ومع ذلك، إذا كان الوقت قد اقترب من موعد الجرعة التالية، فتجاهل الجرعة الفائتة واستمر في تناول الدواء كالمعتاد. إذا نسيت جرعتين أو أكثر، فاتصل بطبيبك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مزدوجة (جرعتين في الوقت نفسه) لتعويض جرعة نسيتها.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول توباماكس </strong></p><p>&nbsp;</p><p dir="RTL">لا يجب التوقف عن تناول هذا الدواء ما لم يطلب منك الطبيب ذلك. قد تعود الأعراض إلى الظهور مرة أخرى. إذا قرر طبيبك المعالج إيقاف هذا الدواء، فيمكنه تقليل الجرعة المخصصة لك تدريجياً في غضون أيام قليلة.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى بشأن استخدام هذا المنتج، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية على الرغم من عدم إصابة الجميع بها.</p><p>&nbsp;</p><p dir="RTL"><strong>أبلغ طبيبك أو اطلب الرعاية الطبية على الفور إذا كنت تعاني من الآثار الجانبية التالية: </strong></p><p dir="RTL"><strong>آثار شائعة جدًا (قد تؤثر على أكثر من </strong><strong>1 من كل </strong><strong>10 أشخاص) </strong>- الاكتئاب (الجديد أو المتفاقم)</p><p dir="RTL"><strong>آثار شائعة (قد تؤثر على ما يصل إلى </strong><strong>1 من كل </strong><strong>10 أشخاص) </strong>- &nbsp;&nbsp; التشنجات (نوبات)&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق أو الانفعالية أو التقلبات المزاجية أو الارتباك أو التوهان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في التركيز أو بطء التفكير أو فقدان الذاكرة أو مشكلات في الذاكرة أو (بداية جديدة أو تغير مفاجئ أو زيادة الخطورة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حصاة كلوية أو كثرة التبول أو التبول بألم</p><p dir="RTL"><strong>آثار غير شائعة (قد تؤثر على ما يصل إلى </strong><strong>1 من كل </strong><strong>100 شخص) </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى الحموضة في الدم (قد تسبب صعوبة في التنفس تشمل ضيق النفس وفقدان الشهية والغثيان والرغبة في القيء والإعياء الشديد وسرعة ضربات القلب أو عدم انتظامها)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض التعرق أو فقدانه (وخاصة عند الأطفال الصغار الذين يتعرضون لدرجات حرارة عالية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود أفكار تلحق الأذى بالنفس ومحاولة إلحاق الأذى بالنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان جزئي للبصر</p><p dir="RTL"><strong>آثار نادرة (قد تؤثر على ما يصل إلى </strong><strong>1 من كل </strong><strong>1000 شخص) </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المياه الزرقاء &ndash; إحصار السوائل في العين مما يؤدي إلى ارتفاع ضغط العين أو حدوث ألم أو انخفاض الرؤية</p><p>&nbsp;</p><p dir="RTL"><strong>فيما يلي آثار جانبية أخرى، إذا ساءت خطورة أي منها، فيرجى إبلاغ الطبيب أو الصيدلي: </strong></p><p>&nbsp;</p><p dir="RTL"><strong>آثار شائعة جدًا (قد تؤثر على أكثر من </strong><strong>1 من كل </strong><strong>10 أشخاص) </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأنف أو سيلان الأنف أو التهاب الحلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بوخز أو ألم و/أو تنميل في أجزاء مختلفة من الجسم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس أو الإرهاق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان أو الإسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خسارة الوزن</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار شائعة (قد تؤثر على ما يصل إلى </strong><strong>1 من كل </strong><strong>10 أشخاص) </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم (انخفاض عدد كرات الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي (مثل الطفح الجلدي أو احمرار الجلد أو الحكة أو تورم في الوجه أو الشرى)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية أو انخفاض الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوان النفسي أو الهياج أو الغضب أو السلوكيات غير الطبيعية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم أو الاستغراق فيه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الكلام أو اضطراب الكلام أو صعوبة في الكلام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخراقة أو غياب التنسيق أو الشعور بعدم الثبات عند المشي&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض القدرة على إنجاز المهام الروتينية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض حاسة التذوق أو فقدانها أو انعدامها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتعاش أو الارتجاف غير الطوعيين أو حركات العين السريعة التي لا يمكن التحكم فيها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب بصري مثل ازدواج الرؤية وتشوش الرؤية وانخفاض الرؤية وصعوبة التركيز</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بعدم الاتزان (دوار) أو وجود طنين في الأذنين أو ألم في الأذن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى أو عدم الارتياح أو الضعف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرغبة في القيء أو الإمساك أو ألم في البطن أو عدم الارتياح أو عسر الهضم أو التهاب المعدة أو الأمعاء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل وتورمها أو تشنجات العضلات أو النفضان أو وجع العضلات أو ضعفها أو ألم الصدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p>&nbsp;</p><p dir="RTL"><strong>آثار غير شائعة (قد تؤثر على ما يصل إلى </strong><strong>1 من كل </strong><strong>100 شخص) </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الصفائح الدموية (كرات الدم التي تساعد على وقف النزيف) أو انخفاض في كرات الدم البيضاء التي تساعد على حمايتك من العدوى أو انخفاض مستوى البوتاسيوم في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في إنزيمات الكبد أو زيادة في اليوزينيات (نوع من كرات الدم البيضاء) في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم غدد الرقبة أو الإبط أو الأربية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المزاج المتهيج</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية أشياء غير موجودة أو سماعها أو الشعور بها أو اضطراب نفسي شديد (الذهان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعامل بدون عاطفة و/أو عدم الإحساس بها أو ارتياب غير عادي أو نوبات الهلع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في القراءة أو اضطراب الكلام أو مشكلات في الكتابة باليد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التململ أو فرط النشاط</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء التفكير أو انخفاض اليقظة أو الانتباه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض حركات الجسم أو بطؤها أو حركات العضلات غير طوعية أو غير طبيعية أو متكررة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاسة اللمس غير طبيعية أو ضعف حاسة اللمس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف حاسة الشم أو خللها أو انعدامها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور أو إحساس غير عاديين قبل الصداع النصفي أو نوع معين من التشنجات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف العين أو حساسية العين تجاه الضوء أو تشنج الجفن أو العيون الدامعة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض السمع أو فقدانه أو فقدان السمع في أذن واحدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء ضربات القلب أو عدم انتظامها أو الشعور بضربات القلب في الصدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم أو انخفاض ضغط الدم عند القيام (وبناءً على ذلك، قد يشعر بعض الأشخاص الذين يتناولون دواء توباماكس بالإغماء أو الدوخة أو قد يفقدون وعيهم عند القيام أو الجلوس فجأة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاحمرار أو الشعور بالدفء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس (التهاب في البنكرياس)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإخراج المفرط للغازات أو الرياح أو حرقة المعدة أو امتلاء البطن أو انتفاخها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف اللثة أو تزايد اللعاب أو سيلان اللعاب أو رائحة النفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإفراط في تناول السوائل أو العطش</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير لون الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب العضلات أو ألم في الجانب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دم في البول أو سلس (عدم السيطرة على) البول أو الرغبة الملحة في التبول أو ألم في الخاصرة أو الكلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة الانتصاب أو الحفاظ عليه أو خلل في الوظائف الجنسية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض تشبه الأنفلونزا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; برودة أصابع اليد أو القدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالسكران</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عجز التعلم</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار نادرة (قد تؤثر على ما يصل إلى </strong><strong>1 من كل </strong><strong>1000 شخص) </strong>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مزاج متهيج بشكل غير طبيعي&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوعي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عمى في عين واحدة أو عمى مؤقت أو عمى ليلي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عين كسولة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في العينين وحولهما</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بتنميل أو وخز في أصابع اليد أو القدم أو تغيير لونها (من الأبيض إلى الأزرق ثم الأحمر) في البرد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد أو الفشل الكبدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعُد متلازمة ستيفنز جونسون حالة ربما تهدد الحياة وقد تستمر مع القرح في مواقع مخاطية متعددة (مثل الفم والأنف والعينين) والطفح الجلدي وظهور تقرحات رائحة غير طبيعية للجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الذراعين والقدمين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب الكلى</p><p>&nbsp;</p><p dir="RTL"><strong>آثار غير معروفة (لا يمكن تقدير مرات تكرار هذه الآثار من البيانات المتاحة) </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اعتلال البقعة هو مرض البقعة التي تعُد بقعة صغيرة في شبكية العين حيث تكون الرؤية حادة. ينبغي أن تتصل بطيبك إذا لاحظت تغييرًا أو انخفاضًا في الرؤية .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُعُد تقشر الأنسجة المتموتة البشروية التسممي حالة ربما تهدد الحياة مرتبطة بمتلازمة ستيفنس جونسون ولكنها أشد خطورة</p><p dir="RTL">منها ويصحبها قرحات واسعة الانتشار وتخشر طبقات الجلد الخارجية (راجع الآثار الجانبية النادرة)</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال </strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">تشبه الآثار الجانبية عند الأطفال بشكل عام تلك التي ظهرت عند البالغين، ولكن الآثار الجانبية التالية قد تكون أكثر شيوعًا عند الأطفال من البالغين:&nbsp;</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في التركيز</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى الحموضة في الدم&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود أفكار تلحق الأذى بالنفس&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإرهاق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية أو زيادتها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوان النفسي أو السلوكيات غير الطبيعية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم أو الاستغراق فيه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بعدم الثبات عند المشي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم الارتياح</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى البوتاسيوم في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعامل بدون عاطفة و/أو عدم الإحساس بها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العيون الدامعة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء ضربات القلب أو عدم انتظامها</p><p>&nbsp;</p><p dir="RTL">فيما يلي الآثار الجانبية الأخرى التي قد تحدث عند الأطفال:</p><p>&nbsp;</p><p dir="RTL"><strong>آثار شائعة (قد تؤثر على ما يصل إلى </strong><strong>1 من كل </strong><strong>10 أشخاص)</strong> - &nbsp;&nbsp; الإحساس بعدم الاتزان (الدوار)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p>&nbsp;</p><p dir="RTL"><strong>آثار غير شائعة (قد تؤثر على ما يصل إلى </strong><strong>1 من كل </strong><strong>100 شخص) </strong>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في اليوزينيات (نوع من كرات الدم البيضاء) في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط النشاط</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدفء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عجز التعلم</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية </strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">إذا ظهرت عليك أي آثار جانبية، فاستشر طبيبك أو الصيدلي. ويتضمن ذلك أي آثار جانبية محتملة غير مُدرجة في هذه النشرة .</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية </strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المملكة العربية السعودية </strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL">المركز الوطني لليقظة الصيدلانية والسلامة الدوائية( NPC) o فاكس: 7662-205-11-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتصل بالمركز الوطني لليقظة الصيدلانية والسلامة الدوائية( NPC) على رقم: 2038222-11-966+، تحويلات: 2340-2334-2354-2353-2356-2317.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رقم الهاتف المجاني: 8002490000</p><p>o&nbsp;&nbsp; &nbsp;<u>npc.drug@sfda.gov.sa</u> :بريد إلكتروني www.sfda.gov.sa/npc :الموقع الإلكتروني o</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>باقي دول مجلس التعاون الخليجي: </strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL">يرجى الاتصال بالسلطة المختصة ذات الصلة.</p></td><td><p>&nbsp;-</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحُفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المحدد على الزجاجة/العلبة الكرتونية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p>&nbsp;</p><p dir="RTL">لا تخُزن الكبسولات عند درجة حرارة&nbsp; أعلى من 25 درجة&nbsp; مئوية&nbsp; وتحُفظ من الرطوبة وتخُزن في العبوة الأصلية محكمة الإغلاق.&nbsp;</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إلى استخدامها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات دواء توباماكس </strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي التوبيراميت.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي كل كبسولة&nbsp; من التوباماكس على 15 أو 25 أو 50 مجم من التوبيراميت.</p><p>&nbsp;</p><p dir="RTL">فيما يلي المكونات الأخرى لدواء التوباماكس:</p><p dir="RTL">الكرات السكرية (نشا الذرة والسكروز) والبوفيدون وأسيتات السليلوز.</p><p>&nbsp;</p><p dir="RTL"><u>الكبسولة</u></p><p dir="RTL">&nbsp;الجيلاتين وثنائي أكسيد التيتانيوم( E171)</p><p>&nbsp;</p><p dir="RTL"><u>حبر الطباعة</u></p><p dir="RTL">&nbsp;الحبر الأسود (أكسيد الحديد الأسود( E172) واللّك المصفى والبروبلين جيلايكول.)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل عبوة توباماكس ومحتوياتها </strong></p><p>&nbsp;</p><p dir="RTL">كبسولات بتركيز 15 مجم: كرات صغيرة بيضاء وبيضاء داكنة في كبسولات الجيلاتين الللنثر باللون الأبيض الداكن المميزة بختم &quot;15 مجم&quot; وختم&quot; TOP&quot; على الغطاء الواضح.</p><p>&nbsp;</p><p dir="RTL">كبسولات بتركيز 25 مجم: كرات صغيرة بيضاء وبيضاء داكنة في كبسولات الجيلاتين الللنثر باللون الأبيض الداكن المميزة بختم &quot;25 مجم&quot; وختم&quot; TOP&quot; على الغطاء الواضح.</p><p>&nbsp;</p><p dir="RTL">كبسولات بتركيز 50 مجم: كرات صغيرة بيضاء وبيضاء داكنة في كبسولات الجيلاتين الللنثر باللون الأبيض الداكن المميزة بختم &quot;50 مجم&quot; وختم&quot; TOP&quot; على الغطاء الواضح.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">زجاجة بلاستيكية غير شفافة مصنوعة من البولي إيثيلين عالي الكثافة( HDPE) مزودة بغطاء لمنع العبث تحتوي على 20 أو 28 أو 60 أو 100كبسولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المصنِّ عة </strong></p><p>&nbsp;</p><p dir="RTL">انظر العلبة الخارجية.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            28 أكتوبر 2015. 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Topimax 15 mg capsules, hard 
Topimax 25 mg capsules, hard Topimax 50 mg capsules, hard 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One capsule contains 15 mg of topiramate. 
One capsule contains 25 mg of topiramate. 
One capsule contains 50 mg of topiramate. 
 
Excipients with known effect: also includes sugar spheres containing not less than 62.5% and not more than 91.5% of sucrose: 
 
One 15 mg capsule contains between 28.1 and 41.2 mg sucrose 
One 25 mg capsule contains between 46.8 and 68.6 mg sucrose 
One 50 mg capsule contains between 93.7 and 137.2 mg sucrose 
 
For the full list of excipients, see section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule. 
 
Description of the product 
 
15 mg: Small white to off-white spheres in Size 2 hard gelatin capsules with white opaque body marked '15 mg’ and clear cap marked 'TOP'. 
25 mg: Small white to off-white spheres in Size 1 hard gelatin capsules with white opaque body marked '25 mg’ and clear cap marked 'TOP'. 
50 mg: Small white to off-white spheres in Size 0 hard gelatin capsules with white opaque body marked '50 mg’ and clear cap marked 'TOP'. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Monotherapy in adults, adolescents and children over 6 years of age with partial seizures with or without secondary generalised seizures, and primary generalised tonic-clonic seizures.</p><p>&nbsp;</p><p>Adjunctive therapy in children aged 2 years and above, adolescents and adults with partial onset seizures with or without secondary generalization or primary generalized tonic-clonic seizures and for the treatment of seizures associated with Lennox-Gastaut syndrome.</p><p>&nbsp;</p><p>Topiramate is indicated in adults for the prophylaxis of migraine headache after careful evaluation of possible alternative treatment options. Topiramate is not intended for acute treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p>&nbsp;</p><p>It is recommended that therapy be initiated at a low dose followed by titration to an effective dose. Dose and titration rate should be guided by clinical response.</p><p>&nbsp;</p><p>It is not necessary to monitor topiramate plasma concentrations to optimize therapy with Topimax. On rare occasions, the addition of topiramate to phenytoin may require an adjustment of the dose of phenytoin to achieve optimal clinical outcome. Addition or withdrawal of phenytoin and carbamazepine to adjunctive therapy with Topimax may require adjustment of the dose of Topimax.</p><p>&nbsp;</p><p>In patients with or without a history of seizures or epilepsy, antiepileptic drugs (AEDs) including topiramate should be gradually withdrawn to minimize the potential for seizures or increased seizure frequency. In clinical trials, daily dosages were decreased in weekly intervals by 50-100 mg in adults with epilepsy and by 25-50 mg in adults receiving topiramate at doses up to 100 mg/day for migraine prophylaxis. In paediatric clinical trials, topiramate was gradually withdrawn over a 2-8 week period.</p><p>&nbsp;</p><p>Monotherapy epilepsy</p><p>&nbsp;</p><p>General</p><p>&nbsp;</p><p>When concomitant AEDs are withdrawn to achieve monotherapy with topiramate, consideration should be given to the effects this may have on seizure control. Unless safety concerns require an abrupt withdrawal of the concomitant AED, a gradual discontinuation at the rate of approximately one-third of the concomitant AED dose every 2 weeks is recommended.</p><p>&nbsp;</p><p>When enzyme inducing medicinal products are withdrawn, topiramate levels will increase. A decrease in Topimax (topiramate) dosage may be required if clinically indicated.</p><p>&nbsp;</p><p>Adults</p><p>&nbsp;</p><p>Dose and titration should be guided by clinical response. Titration should begin at 25 mg nightly for</p><p>1 week. The dosage should then be increased at 1- or 2-week intervals by increments of 25 or 50 mg/day, administered in two divided doses. If the patient is unable to tolerate the titration regimen, smaller increments or longer intervals between increments can be used.</p><p>&nbsp;</p><p>The recommended initial target dose for topiramate monotherapy in adults is 100 mg/day to 200 mg/day in 2 divided doses. The maximum recommended daily dose is 500 mg/day in 2 divided doses. Some patients with refractory forms of epilepsy have tolerated topiramate monotherapy at doses of 1,000 mg/day. These dosing recommendations apply to all adults including the elderly in the absence of underlying renal disease.</p><p>&nbsp;</p><p>Paediatric population (children over 6 years of age)</p><p>&nbsp;</p><p>Dose and titration rate in children should be guided by clinical outcome. Treatment of children over 6 years of age should begin at 0.5 to 1 mg/kg nightly for the first week. The dosage should then be increased at 1 or 2 week intervals by increments of 0.5 to 1 mg/kg/day, administered in two divided doses. If the child is unable to tolerate the titration regimen, smaller increments or longer intervals between dose increments can be used.</p><p>&nbsp;</p><p>The recommended initial target dose range for topiramate monotherapy in children over 6 years of age is 100 mg/day depending on clinical response, (this is about 2.0 mg/kg/day in children 6-16 years).&nbsp;</p><p>&nbsp;</p><p>Adjunctive therapy epilepsy (partial onset seizures with or without secondary generalization, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome)</p><p>&nbsp;</p><p>Adults</p><p>&nbsp;</p><p>Therapy should begin at 25-50 mg nightly for one week. Use of lower initial doses has been reported, but has not been studied systematically. Subsequently, at weekly or bi-weekly intervals, the dose should be increased by 25-50 mg/day and taken in two divided doses. Some patients may achieve efficacy with once-a-day dosing.</p><p>&nbsp;</p><p>In clinical trials as adjunctive therapy, 200 mg was the lowest effective dose. The usual daily dose is 200-400 mg in two divided doses.</p><p>&nbsp;</p><p>These dosing recommendations apply to all adults, including the elderly, in the absence of underlying renal disease (see section 4.4).</p><p>&nbsp;</p><p>Paediatric population (children aged 2 years and above)</p><p>&nbsp;</p><p>The recommended total daily dose of Topimax (topiramate) as adjunctive therapy is approximately 5 to 9 mg/kg/day in two divided doses. Titration should begin at 25 mg (or less, based on a range of 1 to 3 mg/kg/day) nightly for the first week. The dosage should then be increased at 1- or 2-week intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical response.&nbsp;</p><p>&nbsp;</p><p>Daily doses up to 30 mg/kg/day have been studied and were generally well tolerated.&nbsp;</p><p>&nbsp;</p><p>Migraine</p><p>&nbsp;</p><p>Adults</p><p>&nbsp;</p><p>The recommended total daily dose of topiramate for prophylaxis of migraine headache is 100 mg/day administered in two divided doses. Titration should begin at 25 mg nightly for 1 week. The dosage should then be increased in increments of 25 mg/day administered at 1-week intervals. If the patient is unable to tolerate the titration regimen, longer intervals between dose adjustments can be used.</p><p>&nbsp;</p><p>Some patients may experience a benefit at a total daily dose of 50 mg/day. Patients have received a total daily dose up to 200 mg/day. This dose may be benefit in some patients, nevertheless, caution is advised due to an increase incidence of side effects.</p><p>&nbsp;</p><p>Paediatric population</p><p>&nbsp;</p><p>Topimax (topiramate) is not recommended for treatment or prevention of migraine in children due to insufficient data on safety and efficacy.</p><p>&nbsp;</p><p>General dosing recommendations for Topimax in special patient populations</p><p>&nbsp;</p><p>Renal impairment</p><p>&nbsp;</p><p>In patients with impaired renal function (CL<sub>CR</sub> &le; 70 mL/min) topiramate should be administered with caution as the plasma and renal clearance of topiramate are decreased. Subjects with known renal impairment may require a longer time to reach steady-state at each dose. Half of the usual starting and maintenance dose is recommended (see section 5.2).</p><p>&nbsp;</p><p>In patients with end-stage renal failure, since topiramate is removed from plasma by haemodialysis, a supplemental dose of Topimax equal to approximately one-half the daily dose should be administered on haemodialysis days. The supplemental dose should be administered in divided doses at the beginning and completion of the haemodialysis procedure. The supplemental dose may differ based on the characteristics of the dialysis equipment being used (see section 5.2).</p><p>&nbsp;</p><p>Hepatic impairment</p><p>&nbsp;</p><p>In patients with moderate to severe hepatic impairment topiramate should be administered with caution as the clearance of topiramate is decreased.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>&nbsp;</p><p>No dose adjustment is required in the elderly population providing renal function is intact.</p><p>&nbsp;</p><p>Method of administration</p><p>&nbsp;</p><p>Topimax is available in film-coated tablets and a hard capsule formulation, for oral administration. It is recommended that film-coated tablets not be broken. The hard capsule formulation is provided for those patients who cannot swallow tablets, e.g. paediatric and the elderly.</p><p>&nbsp;</p><p>Topimax hard capsules may be swallowed whole or may be administered by carefully opening the capsule and sprinkling the entire contents on a small amount (teaspoon) of soft food. This medicinal product/food mixture is to be swallowed immediately and not chewed. It must not be stored for future use.</p><p>&nbsp;</p><p>Topimax can be taken without regard to meals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
 
Migraine prophylaxis in pregnancy and in women of childbearing potential if not using a highly effective method of contraception. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In situations where rapid withdrawal of topiramate is medically required, appropriate monitoring is recommended (see section 4.2).</p><p>&nbsp;</p><p>As with other AEDs, some patients may experience an increase in seizure frequency or the onset of new types of seizures with topiramate. These phenomena may be the consequence of an overdose, a decrease in plasma concentrations of concomitantly used AEDs, progress of the disease, or a paradoxical effect.</p><p>&nbsp;</p><p>Adequate hydration while using topiramate is very important. Hydration can reduce the risk of nephrolithiasis (see below). Proper hydration prior to and during activities such as exercise or exposure to warm temperatures may reduce the risk of heat-related adverse reactions (see section 4.8).</p><p>&nbsp;</p><p>Oligohydrosis</p><p>&nbsp;</p><p>Oligohydrosis (decreased sweating) has been reported in association with the use of topiramate. Decreased sweating and hyperthermia (rise in body temperature) may occur especially in young children exposed to high ambient temperature.</p><p>&nbsp;</p><p>Mood disturbances/depression</p><p>&nbsp;</p><p>An increased incidence of mood disturbances and depression has been observed during topiramate treatment.</p><p>&nbsp;</p><p>Suicide/suicide ideation</p><p>&nbsp;</p><p>Suicidal ideation and behaviour have been reported in patients treated with antiepileptic agents in several indications. A meta-analysis of randomised placebo-controlled trials of AEDs has shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for topiramate.</p><p>&nbsp;</p><p>In double blind clinical trials, suicide related events (SREs) (suicidal ideation, suicide attempts and suicide) occurred at a frequency of 0.5% in topiramate treated patients (46 out of 8,652 patients treated) and at a nearly 3-fold higher incidence than those treated with placebo (0.2%; 8 out of 4,045 patients treated).</p><p>&nbsp;</p><p>Patients therefore should be monitored for signs of suicidal ideation and behaviour and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.</p><p>&nbsp;</p><p>Nephrolithiasis</p><p>&nbsp;</p><p>Some patients, especially those with a predisposition to nephrolithiasis, may be at increased risk for renal stone formation and associated signs and symptoms such as renal colic, renal pain or flank pain.</p><p>&nbsp;</p><p>Risk factors for nephrolithiasis include prior stone formation, a family history of nephrolithiasis and hypercalciuria. None of these risk factors can reliably predict stone formation during topiramate treatment. In addition, patients taking other medicinal products associated with nephrolithiasis may be at increased risk.</p><p>&nbsp;</p><p>Decreased renal function</p><p>&nbsp;</p><p>In patients with impaired renal function (CL<sub>CR</sub> &le; 70 mL/min) topiramate should be administered with caution as the plasma and renal clearance of topiramate are decreased. For specific posology recommendations in patients with decreased renal function, see section 4.2.</p><p>&nbsp;</p><p>Decreased hepatic function</p><p>&nbsp;</p><p>In hepatically-impaired patients, topiramate should be administered with caution as the clearance of topiramate may be decreased.</p><p>&nbsp;</p><p>Acute myopia and secondary angle closure glaucoma</p><p>&nbsp;</p><p>A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate. Symptoms include acute onset of decreased visual acuity and/or ocular pain. Ophthalmologic findings can include myopia, anterior chamber shallowing, ocular hyperaemia (redness) and increased intraocular pressure. Mydriasis may or may not be present. This syndrome may be associated with supraciliary effusion resulting in anterior displacement of the lens and iris, with secondary angle closure glaucoma. Symptoms typically occur within 1 month of initiating topiramate therapy. In contrast to primary narrow angle glaucoma, which is rare under 40 years of age, secondary angle closure glaucoma associated with topiramate has been reported in paediatric patients as well as adults. Treatment includes discontinuation of topiramate, as rapidly as possible in the judgment of the treating physician, and appropriate measures to reduce intraocular pressure. These measures generally result in a decrease in intraocular pressure.</p><p>&nbsp;</p><p>Elevated intraocular pressure of any aetiology, if left untreated, can lead to serious sequelae including permanent vision loss.</p><p>&nbsp;</p><p>A determination should be made whether patients with history of eye disorders should be treated with topiramate.</p><p>&nbsp;</p><p>Visual field defects</p><p>&nbsp;</p><p>Visual field defects have been reported in patients receiving topiramate independent of elevated intraocular pressure. In clinical trials, most of these events were reversible after topiramate discontinuation. If visual field defects occur at any time during topiramate treatment, consideration should be given to discontinuing the drug.</p><p>&nbsp;</p><p>Metabolic acidosis</p><p>&nbsp;</p><p>Hyperchloremic, non-anion gap, metabolic acidosis (i.e. decreased serum bicarbonate below the normal reference range in the absence of respiratory alkalosis) is associated with topiramate treatment. This decrease in serum bicarbonate is due to the inhibitory effect of topiramate on renal carbonic anhydrase. Generally, the decrease in bicarbonate occurs early in treatment although it can occur at any time during treatment. These decreases are usually mild to moderate (average decrease of 4 mmol/l at doses of 100 mg/day or above in adults and at approximately 6 mg/kg/day in paediatric patients). Rarely, patients have experienced decreases to values below 10 mmol/l. Conditions or therapies that predispose to acidosis (such as renal disease, severe respiratory disorders, status epilepticus, diarrhoea, surgery, ketogenic diet, or certain medicinal products) may be additive to the bicarbonate lowering effects of topiramate.</p><p>&nbsp;</p><p>Chronic metabolic acidosis increases the risk of renal stone formation and may potentially lead to osteopenia.</p><p>&nbsp;</p><p>Chronic metabolic acidosis in paediatric patients can reduce growth rates. The effect of topiramate on bone-related sequelae has not been systematically investigated in paediatric or adult populations.</p><p>&nbsp;</p><p>Depending on underlying conditions, appropriate evaluation including serum bicarbonate levels is recommended with topiramate therapy. If signs or symptoms are present (e.g. Kussmaul&rsquo;s deep breathing, dyspnoea, anorexia, nausea, vomiting, excessive tiredness, tachycardia or arrhythmia), indicative of metabolic acidosis, measurement of serum bicarbonate is recommended. If metabolic acidosis develops and persists, consideration should be given to reducing the dose or discontinuing topiramate (using dose tapering).</p><p>&nbsp;</p><p>Topiramate should be used with caution in patients with conditions or treatments that represent a risk factor for the appearance of metabolic acidosis.</p><p>&nbsp;</p><p>Impairment of cognitive function</p><p>&nbsp;</p><p>Cognitive impairment in epilepsy is multifactorial and may be due to the underlying aetiology, due to the epilepsy or due to the antiepileptic treatment. There have been reports in the literature of impairment of cognitive function in adults on topiramate therapy which required reduction in dosage or discontinuation of treatment. However, studies regarding cognitive outcomes in children treated with topiramate are insufficient and its effect in this regard still needs to be elucidated.</p><p>&nbsp;</p><p>Nutritional supplementation</p><p>&nbsp;</p><p>Some patients may experience weight loss whilst on treatment with topiramate. It is recommended that patients on topiramate treatment should be monitored for weight loss. A dietary supplement or increased food intake may be considered if the patient is losing weight while on topiramate.</p><p>&nbsp;</p><p>Sucrose intolerance</p><p>&nbsp;</p><p>This medicinal product contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects of Topimax on other antiepileptic medicinal products</p><p>&nbsp;</p><p>The addition of Topimax to other AEDs (phenytoin, carbamazepine, valproic acid, phenobarbital, primidone) has no effect on their steady-state plasma concentrations, except in the occasional patient, where the addition of Topimax to phenytoin may result in an increase of plasma concentrations of phenytoin. This is possibly due to inhibition of a specific enzyme polymorphic isoform (CYP2C19). Consequently, any patient on phenytoin showing clinical signs or symptoms of toxicity should have phenytoin levels monitored.&nbsp;</p><p>&nbsp;</p><p>A pharmacokinetic interaction study of patients with epilepsy indicated the addition of topiramate to lamotrigine had no effect on steady state plasma concentration of lamotrigine at topiramate doses of 100 to 400 mg/day. In addition, there was no change in steady state plasma concentration of topiramate during or after removal of lamotrigine treatment (mean dose of 327 mg/day).&nbsp;</p><p>&nbsp;</p><p>Topiramate inhibits the enzyme CYP 2C19 and may interfere with other substances metabolized via this enzyme (e.g., diazepam, imipramin, moclobemide, proguanil, omeprazol).</p><p>&nbsp;</p><p>Effects of other antiepileptic medicinal products on Topimax</p><p>&nbsp;</p><p>Phenytoin and carbamazepine decrease the plasma concentration of topimarate. The addition or withdrawal of phenytoin or carbamazepine to Topimax therapy may require an adjustment in dosage of the latter. This should be done by titrating to clinical effect. The addition or withdrawal of valproic acid does not produce clinically significant changes in plasma concentrations of Topimax and, therefore, does not warrant dosage adjustment of Topimax. The results of these interactions are summarized below:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>AED Coadministered&nbsp; </strong></p></td><td><p><strong>AED Concentration </strong></p></td><td><p><strong>Topimax Concentration </strong></p></td></tr><tr><td><p>Phenytoin&nbsp;</p></td><td><p>&harr;**</p></td><td><p>&darr;</p></td></tr><tr><td><p>Carbamazepine (CBZ)&nbsp;</p></td><td><p>&harr;</p></td><td><p>&darr;</p></td></tr><tr><td><p>Valproic acid&nbsp;</p></td><td><p>&harr;</p></td><td><p>&harr;</p></td></tr><tr><td><p>Lamotrigine&nbsp;</p></td><td><p>&harr;</p></td><td><p>&harr;</p></td></tr><tr><td><p>Phenobarbital&nbsp;</p></td><td><p>&harr;</p></td><td><p>NS</p></td></tr><tr><td><p>Primidone&nbsp;</p></td><td><p>&harr;</p></td><td><p>NS</p></td></tr></tbody></table><p>&nbsp;</p><p>&harr;&nbsp; = No effect on plasma concentration (&le;15% change)&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; = Plasma concentrations increase in individual patients&nbsp;</p><p>&darr;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; = Plasma concentrations decrease&nbsp; NS&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; = Not studied&nbsp;</p><p>AED&nbsp; = antiepileptic drug&nbsp;</p><p>&nbsp;</p><p>Other medicinal product interactions</p><p>&nbsp;</p><p>Digoxin</p><p>&nbsp;</p><p>In a single-dose study, serum digoxin area under plasma concentration curve (AUC) decreased 12% due to concomitant administration of Topimax. The clinical relevance of this observation has not been established. When Topimax is added or withdrawn in patients on digoxin therapy, careful attention should be given to the routine monitoring of serum digoxin.&nbsp;</p><p>&nbsp;</p><p>Central nervous system depressants</p><p><em>&nbsp;</em></p><p>Concomitant administration of Topimax and alcohol or other central nervous system (CNS) depressant medicinal products has not been evaluated in clinical studies. It is recommended that Topimax not be used concomitantly with alcohol or other CNS depressant medicinal products.</p><p>&nbsp;</p><p>St John&rsquo;s Wort (Hypericum perforatum)</p><p><em>&nbsp;</em></p><p>A risk of decreased plasma concentrations resulting in a loss of efficacy could be observed with co-administration of topiramate and St John&rsquo;s Wort. There have been no clinical studies evaluating this potential interaction.</p><p>&nbsp;</p><p>Oral contraceptives</p><p><em>&nbsp;</em></p><p>In a pharmacokinetic interaction study in healthy volunteers with a concomitantly administered combination oral contraceptive product containing 1 mg norethindrone (NET) plus 35 &micro;g ethinyl estradiol (EE), Topimax given in the absence of other medications at doses of 50 to 200 mg/day was not associated with statistically significant changes in mean exposure (AUC) to either component of the oral contraceptive. In another study, exposure to EE was statistically significantly decreased at doses of 200, 400, and 800 mg/day (18%, 21%, and 30%, respectively) when given as adjunctive therapy in epilepsy patients taking valproic acid. In both studies, Topimax (50-200 mg/day in healthy volunteers and 200-800 mg/day in epilepsy patients) did not significantly affect exposure to NET. Although there was a dose dependent decrease in EE exposure for doses between 200-800 mg/day (in epilepsy patients), there was no significant dose dependent change in EE exposure for doses of 50-200 mg/day (in healthy volunteers). The clinical significance of the changes observed is not known. The possibility of decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients taking combination oral contraceptive products with Topimax. Patients taking estrogen containing contraceptives should be asked to report any change in their bleeding patterns. Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding.</p><p>&nbsp;</p><p>Lithium</p><p><em>&nbsp;</em></p><p>In healthy volunteers, there was an observed reduction (18% for AUC) in systemic exposure for lithium during concomitant administration with topiramate 200 mg/day. In patients with bipolar disorder, the pharmacokinetics of lithium were unaffected during treatment with topiramate at doses of 200 mg/day; however, there was an observed increase in systemic exposure (26% for AUC) following topiramate doses of up to 600 mg/day. Lithium levels should be monitored when co-administered with topiramate.&nbsp;</p><p>&nbsp;</p><p>Risperidone</p><p><em>&nbsp;</em></p><p>Drug-drug interaction studies conducted under single dose conditions in healthy volunteers and multiple dose conditions in patients with bipolar disorder, yielded similar results. When administered concomitantly with topiramate at escalating doses of 100, 250 and 400 mg/day there was a reduction in risperidone (administered at doses ranging from 1 to 6 mg/day) systemic exposure (16% and 33% for steady-state AUC at the 250 and 400 mg/day doses, respectively). However, differences in AUC for the total active moiety between treatment with risperidone alone and combination treatment with topiramate were not statistically significant.Minimal alterations in the pharmacokinetics of the total active moiety (risperidone plus 9-hydroxyrisperidone) and no alterations for 9-hydroxyrisperidone were observed. There were no significant changes in the systemic exposure of the risperidone total active moiety or of topiramate. When topiramate was added to existing risperidone (1-6 mg/day) treatment, adverse events were reported more frequently than prior to topiramate (250-400 mg/day) introduction (90% and 54% respectively). The most frequently reported AE&rsquo;s when topiramate was added to risperidone treatment were: somnolence (27% and 12%), paraesthesia (22% and 0%) and nausea (18% and 9% respectively).</p><p>&nbsp;</p><p>Hydrochlorothiazide (HCTZ)</p><p><em>&nbsp;</em></p><p>A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of HCTZ (25 mg every 24 h) and topiramate (96 mg every 12 h) when administered alone and concomitantly. The results of this study indicate that topiramate C<sub>max</sub> increased by 27% and AUC increased by 29% when HCTZ was added to topiramate. The clinical significance of this change is unknown. The addition of HCTZ to topiramate therapy may require an adjustment of the topiramate dose. The steady-state pharmacokinetics of HCTZ were not significantly influenced by the concomitant administration of topiramate. Clinical laboratory results indicated decreases in serum potassium after topiramate or HCTZ administration, which were greater when HCTZ and topiramate were administered in combination.</p><p>&nbsp;</p><p>Metformin</p><p><em>&nbsp;</em></p><p>A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of metformin and topiramate in plasma when metformin was given alone and when metformin and topiramate were given simultaneously. The results of this study indicated that metformin mean C<sub>max</sub> and mean AUC<sub>0-12h</sub> increased by 18% and 25%, respectively, while mean CL/F decreased 20% when metformin was co-administered with topiramate. Topiramate did not affect metformin t<sub>max</sub>.<sub> </sub>The clinical significance of the effect of topiramate on metformin pharmacokinetics is unclear. Oral plasma clearance of topiramate appears to be reduced when administered with metformin. The extent of change in the clearance is unknown. The clinical significance of the effect of metformin on topiramate pharmacokinetics is unclear.</p><p>&nbsp;</p><p>When Topimax is added or withdrawn in patients on metformin therapy, careful attention should be given to the routine monitoring for adequate control of their diabetic disease state.</p><p>&nbsp;</p><p>Pioglitazone</p><p><em>&nbsp;</em></p><p>A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of topiramate and pioglitazone when administered alone and concomitantly. A 15% decrease in the AUC<sub>&tau;,ss</sub> of pioglitazone with no alteration in C<sub>max,ss</sub> was observed. This finding was not statistically significant. In addition, a 13% and 16% decrease in C<sub>max,ss</sub> and AUC<sub>&tau;,ss</sub> respectively, of the active hydroxy-metabolite was noted as well as a 60% decrease in C<sub>max,ss </sub>and AUC<sub>&tau;,ss</sub> of the active keto-metabolite. The clinical significance of these findings is not known. When Topimax is added to pioglitazone therapy or pioglitazone is added to Topimax therapy, careful attention should be given to the routine monitoring of patients for adequate control of their diabetic disease state.&nbsp;</p><p>&nbsp;</p><p>Glyburide</p><p><em>&nbsp;</em></p><p>A drug-drug interaction study conducted in patients with type 2 diabetes evaluated the steady-state pharmacokinetics of glyburide (5 mg/day) alone and concomitantly with topiramate (150 mg/day). There was a 25% reduction in glyburide AUC<sub>24</sub> during topiramate administration. Systemic exposure of the active metabolites, 4-<em>trans</em>-hydroxy-glyburide (M1) and 3-<em>cis</em>-hydroxyglyburide (M2), were also reduced by 13% and 15%, respectively. The steady-state pharmacokinetics of topiramate were unaffected by concomitant administration of glyburide.</p><p>&nbsp;</p><p>When topiramate is added to glyburide therapy or glyburide is added to topiramate therapy, careful attention should be given to the routine monitoring of patients for adequate control of their diabetic disease state.&nbsp;</p><p>&nbsp;</p><p>Other forms of interactions</p><p>&nbsp;</p><p>Agents predisposing to nephrolithiasis</p><p>&nbsp;</p><p>Topimax, when used concomitantly with other agents predisposing to nephrolithiasis, may increase the risk of nephrolithiasis. While using Topimax, agents like these should be avoided since they may create a physiological environment that increases the risk of renal stone formation.&nbsp;</p><p>&nbsp;</p><p>Valproic acid</p><p><em>&nbsp;</em></p><p>Concomitant administration of topiramate and valproic acid has been associated with hyperammonemia with or without encephalopathy in patients who have tolerated either medicinal product alone. In most cases, symptoms and signs abated with discontinuation of either medicinal product. This adverse reaction is not due to a pharmacokinetic interaction. An association of hyperammonemia with topiramate monotherapy or concomitant treatment with other AEDs has not been established.&nbsp;</p><p>&nbsp;</p><p>Hypothermia, defined as an unintentional drop in body core temperature to &lt;35&deg;C, has been reported in association with concomitant use of topiramate and valproic acid (VPA) both in conjunction with hyperammonemia and in the absence of hyperammonemia. This adverse event in patients using concomitant topiramate and valproate can occur after starting topiramate treatment or after increasing the daily dose of topiramate.</p><p>&nbsp;</p><p>Additional pharmacokinetic drug interaction studies</p><p>&nbsp;</p><p>Clinical studies have been conducted to assess the potential pharmacokinetic drug interaction between topiramate and other agents. The changes in C<sub>max</sub> or AUC as a result of the interactions are summarized below. The second column (concomitant drug concentration) describes what happens to the concentration of the concomitant drug listed in the first column when topiramate is added. The third column (topiramate concentration) describes how the coadministration of a drug listed in the first column modifies the concentration of topiramate.&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3"><p><strong>Summary of Results from Additional Clinical Pharmacokinetic Drug Interaction Studies </strong></p></td></tr><tr><td><p><strong>Concomitant Drug&nbsp; </strong></p></td><td><p><strong>Concomitant Drug Concentration<sup>a</sup> </strong></p></td><td><p><strong>Topiramate Concentration<sup>a</sup> </strong></p></td></tr><tr><td><p>Amitriptyline&nbsp;</p></td><td><p>&harr; 20% increase in C<sub>max</sub> and</p><p>AUC of nortriptyline metabolite</p></td><td><p>NS</p></td></tr><tr><td><p>Dihydroergotamine (Oral and Subcutaneous)&nbsp;</p></td><td><p>&harr;</p></td><td><p>&harr;</p></td></tr><tr><td><p>Haloperidol&nbsp;</p></td><td><p>&harr; 31% increase in AUC of the</p><p>reduced metabolite&nbsp;</p></td><td><p>NS</p></td></tr><tr><td><p>Propranolol&nbsp;</p></td><td><p>&harr; 17% increase in C<sub>max</sub> for</p><p>4-OH propranolol (TPM 50 mg q12h)&nbsp;</p></td><td><p>9% and 16% increase in C<sub>max</sub>,&nbsp;</p><p>9% and17% increase in AUC</p><p>(40 and 80 mg propranolol q12h respectively)&nbsp;</p></td></tr><tr><td><p>Sumatriptan (Oral and Subcutaneous)&nbsp;</p></td><td><p>&harr;</p></td><td><p>NS</p></td></tr><tr><td><p>Pizotifen&nbsp;</p></td><td><p>&harr;</p></td><td><p>&harr;</p></td></tr><tr><td><p>Diltiazem&nbsp;</p></td><td><p>25% decrease in AUC of diltiazem and 18% decrease in</p><p>DEA, and &harr; for DEM*&nbsp;</p></td><td><p>20% increase in AUC&nbsp;</p></td></tr><tr><td><p>Venlafaxine&nbsp;</p></td><td><p>&harr;</p></td><td><p>&harr;</p></td></tr><tr><td><p>Flunarizine&nbsp;</p></td><td><p>16% increase in AUC&nbsp; (TPM 50 mg q12h)<sup>b</sup></p></td><td><p>&harr;</p></td></tr><tr><td colspan="3"><p><strong>Summary of Results from Additional Clinical Pharmacokinetic Drug Interaction Studies </strong></p></td></tr><tr><td><p><strong>Concomitant Drug&nbsp; </strong></p></td><td><p><strong>Concomitant Drug Concentration<sup>a</sup> </strong></p></td><td><p><strong>Topiramate Concentration<sup>a</sup> </strong></p></td></tr></tbody></table><p>&nbsp;</p><p><sup>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>=&nbsp; % values are the changes in treatment mean C<sub>max</sub> or AUC with respect to monotherapy&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; &harr;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; =&nbsp; No effect on C<sub>max</sub> and AUC (&le;15% change) of the parent compound&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; NS&nbsp; &nbsp;&nbsp;&nbsp; =&nbsp; Not studied&nbsp;</p><p>*DEA =&nbsp; des acetyl diltiazem, DEM = N-demethyl diltiazem&nbsp;</p><p><sup>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>=&nbsp; Flunarizine AUC increased 14% in subjects taking flunarizine alone. Increase in exposure may be attributed to accumulation during achievement of steady state.&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy&nbsp;</p><p>&nbsp;</p><p>Risk related to epilepsy and AEDs in general</p><p>&nbsp;</p><p>Specialist advice should be given to women who are of childbearing potential. The need for treatment with AEDs should be reviewed when a woman is planning to become pregnant. In women being treated for epilepsy, sudden discontinuation of AED therapy should be avoided as this may lead to breakthrough seizures that could have serious consequences for the woman and the unborn child. Monotherapy should be preferred whenever possible because therapy with multiple AEDs could be associated with a higher risk of congenital malformations than monotherapy, depending on the associated antiepileptics.</p><p>&nbsp;</p><p>Risk related to topiramate</p><p><em>&nbsp;</em></p><p>Topiramate was teratogenic in mice, rats and rabbits (see section 5.3). In rats, topiramate crosses the placental barrier.</p><p>&nbsp;</p><p>Clinical data from pregnancy registries indicate that infants exposed to topiramate monotherapy have:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increased risk of congenital malformations (particularly cleft lip/palate, hypospadias, and anomalies involving various body systems) following exposure during the first trimester. The North American Antiepileptic Drug pregnancy registry data for topiramate monotherapy showed an approximate 3-fold higher incidence of major congenital malformations, compared with a reference group not taking AEDs. In addition, data from other studies indicate that, compared with monotherapy, there is an increased risk of teratogenic effects associated with the use of AEDs in combination therapy.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A higher prevalence of low birth weight (&lt;2500 grams) compared with a reference group.&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increased prevalence of being small for gestational age (SGA; defined as birth weight below the 10<sup>th</sup> percentile corrected for their gestational age, stratified by sex). The long term consequences of the SGA findings could not be determined.</p><p>&nbsp;</p><p>It is recommended that women of child bearing potential use highly effective contraception (see section 4.5) and consider alternative therapeutic options.</p><p>&nbsp;</p><p>Indication epilepsy</p><p>&nbsp;</p><p>It is recommended to consider alternative therapeutic options in women of child bearing potential. If topirmate is used in women of child bearing potential, it is recommended that highly effective contraception be used (see section 4.5), and that the woman is fully informed of the known risks of uncontrolled epilepsy to the pregnancy and the potential risks of the medicinal product to the foetus. If a woman plans a pregnancy, a preconceptional visit is recommended in order to reassess the treatment, and to consider other therapeutic options. In case of administration during the first trimester, careful prenatal monitoring should be performed.</p><p>&nbsp;</p><p>Indication migraine prophylaxis</p><p>&nbsp;</p><p>Topiramate is contraindicated in pregnancy and in women of childbearing potential if a highly effective method of contraception is not used (see sections 4.3 and 4.5).</p><p>&nbsp;</p><p>Breast-feeding</p><p>&nbsp;</p><p>Animal studies have shown excretion of topiramate in milk. The excretion of topiramate in human milk has not been evaluated in controlled studies. Limited observations in patients suggest an extensive excretion of topiramate into breast milk. Since many medicinal products are excreted into human milk, a decision must be made whether to suspend breast-feeding or to discontinue/ abstain from topiramate therapy taking into account the importance of the medicinal product to the mother (see section 4.4).</p><p>&nbsp;</p><p>Fertility</p><p>&nbsp;</p><p>Animal studies did not reveal impairment of fertility by topiramate (see section 5.3). The effect of topiramate on human fertility has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Topimax has minor or moderate influence on the ability to drive and use machines. Topiramate acts on the central nervous system and may produce drowsiness, dizziness or other related symptoms. It may also cause visual disturbances and/or blurred vision. These adverse reactions could potentially be dangerous in patients driving a vehicle or operating machinery, particularly until such time as the individual patient&#39;s experience with the medicinal products established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety of topiramate was evaluated from a clinical trial database consisting of 4,111 patients (3,182 on topiramate and 929 on placebo) who participated in 20 double-blind trials and 2,847 patients who participated in 34 open-label trials, respectively, for topiramate as adjunctive treatment of primary generalized tonic-clonic seizures, partial onset seizures, seizures associated with Lennox-Gastaut syndrome, monotherapy for newly or recently diagnosed epilepsy or migraine prophylaxis. The majority of adverse reactions were mild to moderate in severity. Adverse reactions identified in clinical trials, and during post-marketing experience (as indicated by &ldquo;*&rdquo;) are listed by their incidence in clinical trials in Table 1. Assigned frequencies are as follows:</p><p>&nbsp;</p><p>Very common</p><p>Common &nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;</p><p>Uncommon&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/1,000 to &lt;1/100</p><p>Rare&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/10,000 to &lt;1/1,000&nbsp;</p><p>Not known&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cannot be estimated from the available data</p><p>&nbsp;</p><p>The most common adverse reactions (those with an incidence of &gt;5% and greater than that observed in placebo in at least 1 indication in double-blind controlled studies with topiramate) include: anorexia, decreased appetite, bradyphrenia, depression, expressive language disorder, insomnia, coordination abnormal, disturbance in attention, dizziness, dysarthria, dysgeusia, hypoesthesia, lethargy, memory impairment, nystagmus, paresthesia, somnolence, tremor, diplopia, vision blurred, diarrhoea, nausea, fatigue, irritability, and weight decreased.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td colspan="4"><p><strong>Table 1: Topiramate Adverse Reactions </strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>System Organ Class </strong></p></td><td><p><strong>Very common </strong></p></td><td><p><strong>Common </strong></p></td><td><p><strong>Uncommon </strong></p></td><td><p><strong>Rare </strong></p></td><td><p><strong>Not known </strong></p></td></tr><tr><td><p>Infections and infestations</p></td><td><p>Nasopharyngitis*</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="6"><p><strong>Table 1: Topiramate Adverse Reactions </strong></p></td></tr><tr><td><p><strong>System Organ Class </strong></p></td><td><p><strong>Very common </strong></p></td><td><p><strong>Common </strong></p></td><td><p><strong>Uncommon </strong></p></td><td><p><strong>Rare </strong></p></td><td><p><strong>Not known </strong></p></td></tr><tr><td><p>Blood and lymphatic system disorders&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Anaemia</p></td><td><p>Leucopenia, thrombocytopenia lymphadenopathy, eosinophilia</p></td><td><p>Neutropenia*</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Immune system disorders</p></td><td><p>&nbsp;</p></td><td><p>Hypersensitivity</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Allergic oedema*</p></td></tr><tr><td><p>Metabolism and nutrition disorders</p></td><td><p>&nbsp;</p></td><td><p>Anorexia, decreased appetite</p></td><td><p>Metabolic acidosis, hypokalaemia, increased appetite, polydipsia</p></td><td><p>Acidosis hyperchloraemic</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Psychiatric disorders</p></td><td><p>Depression</p></td><td><p>Bradyphrenia, insomnia, expressive language disorder, anxiety, confusional state, disorientation, aggression, mood altered, agitation, mood swings, depressed mood, anger, abnormal behaviour</p></td><td><p>Suicidal ideation, suicide attempt, hallucination, psychotic disorder, hallucination auditory, hallucination visual, apathy, lack of spontaneous speech, sleep disorder, affect lability, libido decreased, restlessness, crying, dysphemia, euphoric mood, paranoia, perseveration, panic attack, tearfulness, reading disorder, initial insomnia, flat affect, thinking abnormal, loss of libido, listless, middle insomnia,</p><p>distractibility, early morning awakening, panic</p><p>reaction, elevated mood&nbsp;</p></td><td><p>Mania, panic disorder, feeling of despair*, hypomania&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="6"><p><strong>Table 1: Topiramate Adverse Reactions </strong></p></td></tr><tr><td><p><strong>System Organ Class </strong></p></td><td><p><strong>Very common </strong></p></td><td><p><strong>Common </strong></p></td><td><p><strong>Uncommon </strong></p></td><td><p><strong>Rare </strong></p></td><td><p><strong>Not known </strong></p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>Paraesthesia, somnolence Dizziness&nbsp;</p></td><td><p>Disturbance in attention, memory impairment, amnesia, cognitive disorder, mental impairment, psychomotor skills impaired, convulsion, coordination abnormal, tremor, lethargy, hypoaesthesia, nystagmus, dysgeusia, balance disorder, dysarthria, intention tremor, sedation&nbsp;</p></td><td><p>Depressed level of consciousness, grand mal convulsion, visual field defect, complex partial</p><p>&nbsp;seizures, speech</p><p>disorder, psychomotor hyperactivity, syncope, sensory disturbance, drooling, hypersomnia, aphasia, repetitive</p><p>speech, hypokinesia, dyskinesia, dizziness postural, poor quality sleep, burning sensation, sensory loss, parosmia, cerebellar syndrome, dysaesthesia, hypogeusia, stupor, clumsiness, aura, ageusia, dysgraphia, dysphasia, neuropathy peripheral, presyncope, dystonia, formication</p></td><td><p>Apraxia, circadian rhythm sleep disorder, hyperaesthesia, hyposmia, anosmia, essential tremor, akinesia, unresponsive to stimuli</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Eye disorders</p></td><td><p>&nbsp;</p></td><td><p>Vision blurred, diplopia, visual disturbance</p></td><td><p>Visual acuity reduced, scotoma, myopia*, abnormal sensation in eye*, dry eye, photophobia, blepharospasm, lacrimation increased, photopsia, mydriasis, presbyopia</p></td><td><p>Blindness unilateral, blindness transient, glaucoma,</p><p>accommodation</p><p>disorder, altered visual depth perception, scintillating scotoma, eyelid oedema*, night blindness, amblyopia</p></td><td><p>Angle closure glaucoma*, Maculopathy*, eye movement disorder*, conjunctival oedema*</p></td></tr><tr><td><p>Ear and labyrinth disorders</p></td><td><p>&nbsp;</p></td><td><p>Vertigo, tinnitus, ear pain</p></td><td><p>Deafness, deafness unilateral, deafness neurosensory, ear discomfort, hearing impaired</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Cardiac disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Bradycardia, sinus bradycardia, palpitations&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="6"><p><strong>Table 1: Topiramate Adverse Reactions </strong></p></td></tr><tr><td><p><strong>System Organ Class </strong></p></td><td><p><strong>Very common </strong></p></td><td><p><strong>Common </strong></p></td><td><p><strong>Uncommon </strong></p></td><td><p><strong>Rare </strong></p></td><td><p><strong>Not known </strong></p></td></tr><tr><td><p>Vascular disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Hypotension, orthostatic hypotension, flushing, hot flush</p></td><td><p>Raynaud&#39;s phenomenon</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>&nbsp;</p></td><td><p>Dyspnoea,</p><p>epistaxis, nasal congestion, rhinorrhoea, cough*</p></td><td><p>Dyspnoea</p><p>exertional,</p><p>Paranasal sinus hypersecretion, dysphonia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Gastrointestinal disorders&nbsp;</p></td><td><p>Nausea, diarrhoea</p></td><td><p>Vomiting, constipation, abdominal pain upper, dyspepsia, abdominal pain, dry mouth, stomach discomfort, paraesthesia oral, gastritis,</p><p>abdominal discomfort</p></td><td><p>Pancreatitis, flatulence, gastrooesophageal reflux disease, abdominal pain lower,</p><p>hypoaesthesia oral, gingival bleeding, abdominal distension, epigastric discomfort, abdominal tenderness, salivary hypersecretion, oral pain, breath odour, glossodynia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Hepatobiliary disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Hepatitis, Hepatic failure</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Alopecia, rash, pruritus</p></td><td><p>Anhidrosis, hypoaesthesia</p><p>facial, urticaria, erythema, pruritus generalised, rash macular, skin discolouration, dermatitis allergic, swelling face</p></td><td><p>Stevens-Johnson syndrome* erythema multiforme*, skin odour abnormal, periorbital oedema*, urticaria localised&nbsp;</p></td><td><p>Toxic epidermal necrolysis*</p></td></tr><tr><td><p>Musculoskeletal and connective tissue disorders</p></td><td><p>&nbsp;</p></td><td><p>Arthralgia, muscle spasms, myalgia, muscle twitching, muscular weakness, musculoskeletal chest pain&nbsp;</p></td><td><p>Joint swelling*, musculoskeletal stiffness, flank pain, muscle fatigue</p></td><td><p>Limb discomfort*</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Renal and urinary disorders</p></td><td><p>&nbsp;</p></td><td><p>Nephrolithiasis, pollakiuria, dysuria</p></td><td><p>Calculus urinary, urinary incontinence, haematuria, incontinence, micturition urgency, renal colic, renal pain</p></td><td><p>Calculus ureteric, renal tubular acidosis*&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Reproductive system and breast disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Erectile</p><p>dysfunction, sexual dysfunction</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p><strong>Table 1: Topiramate Adverse Reactions </strong></p></td></tr><tr><td><p><strong>System Organ Class </strong></p></td><td><p><strong>Very common </strong></p></td><td><p><strong>Common </strong></p></td><td><p><strong>Uncommon </strong></p></td><td><p><strong>Rare </strong></p></td><td><p><strong>Not known </strong></p></td></tr><tr><td><p>General disorders and administration site conditions</p></td><td><p>Fatigue</p></td><td><p>Pyrexia, asthenia,</p><p>irritability, gait disturbance, feeling abnormal, malaise</p></td><td><p>Hyperthermia, thirst, influenza like illness*, sluggishness, peripheral coldness, feeling drunk, feeling jittery</p></td><td><p>Face oedema,&nbsp; calcinosis</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Investigations</p></td><td><p>Weight decreased</p></td><td><p>&nbsp;Weight increased*</p></td><td><p>Crystal urine present, tandem gait test abnormal, white blood cell count decreased, Increase in liver enzymes</p></td><td><p>Blood bicarbonate decreased</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Social circumstances</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Learning disability</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>* identified as an adverse reaction from postmarketing spontaneous reports. Its frequency was calculated based on clinical trial data.</p><p>&nbsp;</p><p>Paediatric population</p><p>&nbsp;</p><p>Adverse reactions reported more frequently (<sub>&ge;</sub>2-fold) in children than in adults in double-blind controlled studies include:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased appetite</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperchloraemic acidosis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypokalaemia</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal behaviour</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aggression</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Apathy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Initial insomnia</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suicidal ideation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disturbance in attention</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lethargy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Circadian rhythm sleep disorder</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Poor quality sleep</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lacrimation increased</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sinus bradycardia &bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling abnormal</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gait disturbance.</p><p>&nbsp;</p><p>Adverse reactions that were reported in children but not in adults in double-blind controlled studies include:&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eosinophilia</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Psychomotor hyperactivity</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vertigo</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperthermia &bull; &nbsp;&nbsp; Pyrexia</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Learning disability.</p><p>&nbsp;</p><p>Reporting of suspected adverse reactions</p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product</p><p><strong>&nbsp;</strong></p><p><strong>To Report any side effect (s) : </strong></p><p><strong>&nbsp;</strong></p><p>&bull; Saudi Arabia<em> </em></p><p><em>&nbsp;</em></p><p><strong><sup>&nbsp;</sup></strong>The National Pharmacovigilance and Drug Safety Centre (NPC) <strong><sup>&nbsp;</sup></strong>o Fax: +966-11-205-7662 <strong><sup>&nbsp;</sup></strong>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p><sup>&nbsp;</sup>o Toll free phone: 8002490000</p><p>&bull; o E-mail: <strong><em>Other GCC States: </em></strong><u>npc.drug@sfda.gov.sa</u></p><p><strong><sup>&nbsp;</sup></strong>o Website: www.sfda.gov.sa/npc</p><p><strong>&nbsp;</strong>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&bull; &nbsp;&nbsp;&nbsp; <strong>Other GCC states : </strong></p><p><strong><sup>&nbsp;</sup></strong>&nbsp;<sub>&minus; </sub>Please contact the relevant competent authority.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Signs and symptoms</p><p>&nbsp;</p><p>Overdoses of topiramate have been reported. Signs and symptoms included convulsions, drowsiness, speech disturbances, blurred vision, diplopia, impaired mentation, lethargy, abnormal coordination, stupor, hypotension, abdominal pain, agitation, dizziness and depression. The clinical consequences were not severe in most cases, but deaths have been reported after overdoses with multiple medicinal products including topiramate.&nbsp;</p><p>&nbsp;</p><p>Topiramate overdose can result in severe metabolic acidosis (see section 4.4).</p><p>&nbsp;</p><p>Treatment</p><p>&nbsp;</p><p>In acute topiramate overdose, if the ingestion is recent, the stomach should be emptied immediately by lavage or by induction of emesis. Activated charcoal has been shown to adsorb topiramate <em>in vitro</em>. Treatment should be appropriately supportive and the patient should be well hydrated. Haemodialysis has been shown to be an effective means of removing topiramate from the body.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antiepileptics, other antiepileptics, antimigraine preparations, ATC code:</p><p>N03AX11</p><p><em>&nbsp;</em></p><p>Topiramate is classified as a sulfamate-substituted monosaccharide. The precise mechanism by which topiramate exerts its antiseizure and migraine prophylaxis effects are unknown. Electrophysiological and biochemical studies on cultured neurons have identified three properties that may contribute to the antiepileptic efficacy of topiramate.&nbsp;</p><p>&nbsp;</p><p>Action potentials elicited repetitively by a sustained depolarization of the neurons were blocked by topiramate in a time-dependent manner, suggestive of a state-dependent sodium channel blocking action. Topiramate increased the frequency at which &gamma;-aminobutyrate (GABA) activated GABA<sub>A</sub> receptors, and enhanced the ability of GABA to induce a flux of chloride ions into neurons, suggesting that topiramate potentiates the activity of this inhibitory neurotransmitter.</p><p>&nbsp;</p><p>This effect was not blocked by flumazenil, a benzodiazepine antagonist, nor did topiramate increase the duration of the channel open time, differentiating topiramate from barbiturates that modulate GABA<sub>A</sub> receptors.</p><p>&nbsp;</p><p>Because the antiepileptic profile of topiramate differs markedly from that of the benzodiazepines, it may modulate a benzodiazepine-insensitive subtype of GABA<sub>A</sub> receptor. Topiramate antagonized the ability of kainate to activate the kainate/AMPA (&alpha; -amino-3-hydroxy-5-methylisoxazole-4-propionic acid) subtype of excitatory amino acid (glutamate) receptor, but had no apparent effect on the activity of N-methyl-D-aspartate (NMDA) at the NMDA receptor subtype. These effects of topiramate were concentration-dependent over a range of 1 &micro;M to 200 &micro;M, with minimum activity observed at 1 &micro;M to 10 &micro;M.</p><p>&nbsp;</p><p>In addition, topiramate inhibits some isoenzymes of carbonic anhydrase. This pharmacologic effect is much weaker than that of acetazolamide, a known carbonic anhydrase inhibitor, and is not thought to be a major component of topiramate&#39;s antiepileptic activity.</p><p>&nbsp;</p><p>In animal studies, topiramate exhibits anticonvulsant activity in rat and mouse maximal electroshock seizure (MES) tests and is effective in rodent models of epilepsy, which include tonic and absence-like seizures in the spontaneous epileptic rat (SER) and tonic and clonic seizures induced in rats by kindling of the amygdala or by global ischemia. Topiramate is only weakly effective in blocking clonic seizures induced by the GABA<sub>A</sub> receptor antagonist, pentylenetetrazole.</p><p>&nbsp;</p><p>Studies in mice receiving concomitant administration of topiramate and carbamazepine or phenobarbital showed synergistic anticonvulsant activity, while combination with phenytoin showed additive anticonvulsant activity. In well-controlled add-on trials, no correlation has been demonstrated between trough plasma concentrations of topiramate and its clinical efficacy. No evidence of tolerance has been demonstrated in man.</p><p>&nbsp;</p><p>Absence seizures</p><p>&nbsp;</p><p>Two small one arm studies were carried out with children aged 4-11 years old (CAPSS-326 and TOPAMAT-ABS-001). One included 5 children and the other included 12 children before it was terminated early due to lack of therapeutic response. The doses used in these studies were up to approximately 12 mg/kg in study TOPAMAT-ABS-001 and a maximum of the lesser of 9 mg/kg/day or 400 mg/day in study CAPSS-326. These studies do not provide sufficient evidence to reach conclusion regarding efficacy or safety in the paediatric population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The film-coated tablet and hard capsule formulations are bioequivalent.</p><p>&nbsp;</p><p>The pharmacokinetic profile of topiramate compared to other AEDs shows a long plasma half-life, linear pharmacokinetics, predominantly renal clearance, absence of significant protein binding, and lack of clinically relevant active metabolites.</p><p>&nbsp;</p><p>Topiramate is not a potent inducer of drug metabolizing enzymes, can be administered without regard to meals, and routine monitoring of plasma topiramate concentrations is not necessary. In clinical studies, there was no consistent relationship between plasma concentrations and efficacy or adverse events.</p><p>&nbsp;</p><p>Absorption</p><p>&nbsp;</p><p>Topiramate is rapidly and well absorbed. Following oral administration of 100 mg topiramate to healthy subjects, a mean peak plasma concentration (C<sub>max</sub>) of 1.5 &micro;g/ml was achieved within 2 to</p><p>3 hours (T<sub>max</sub>).</p><p>&nbsp;</p><p>Based on the recovery of radioactivity from the urine the mean extent of absorption of a 100 mg oral dose of <sup>14</sup>C-topiramate was at least 81%. There was no clinically significant effect of food on the bioavailability of topiramate.</p><p>&nbsp;</p><p>Distribution</p><p>&nbsp;</p><p>Generally, 13 to 17% of topiramate is bound to plasma protein. A low capacity binding site for topiramate in/on erythrocytes that is saturable above plasma concentrations of 4 &micro;g/ml has been observed. The volume of distribution varied inversely with the dose. The mean apparent volume of distribution was 0.80 to 0.55 l/kg for a single dose range of 100 to 1200 mg. An effect of gender on the volume of distribution was detected, with values for females circa 50% of those for males. This was attributed to the higher percent body fat in female patients and is of no clinical consequence.</p><p>&nbsp;</p><p>Biotransformation</p><p>&nbsp;</p><p>Topiramate is not extensively metabolized (~20%) in healthy volunteers. It is metabolized up to 50% in patients receiving concomitant antiepileptic therapy with known inducers of drug metabolizing enzymes. Six metabolites, formed through hydroxylation, hydrolysis and glucuronidation, have been isolated, characterized and identified from plasma, urine and faeces of humans. Each metabolite represents less than 3% of the total radioactivity excreted following administration of <sup>14</sup>C-topiramate. Two metabolites, which retained most of the structure of topiramate, were tested and found to have little or no anticonvulsant activity.</p><p>&nbsp;</p><p>Elimination</p><p>&nbsp;</p><p>In humans, the major route of elimination of unchanged topiramate and its metabolites is via the kidney (at least 81% of the dose). Approximately 66% of a dose of <sup>14</sup>C-topiramate was excreted unchanged in the urine within four days. Following twice a day dosing with 50 mg and 100 mg of topiramate the mean renal clearance was approximately 18 ml/min and 17 ml/min, respectively. There is evidence of renal tubular reabsorption of topiramate. This is supported by studies in rats where topiramate was co-administered with probenecid, and a significant increase in renal clearance of topiramate was observed. Overall, plasma clearance is approximately 20 to 30 ml/min in humans following oral administration.</p><p>&nbsp;</p><p>Linearity/non-linearity</p><p>&nbsp;</p><p>Topiramate exhibits low intersubject variability in plasma concentrations and, therefore, has predictable pharmacokinetics. The pharmacokinetics of topiramate are linear with plasma clearance remaining constant and area under the plasma concentration curve increasing in a dose-proportional manner over a 100 to 400 mg single oral dose range in healthy subjects. Patients with normal renal function may take 4 to 8 days to reach steady-state plasma concentrations. The mean C<sub>max</sub> following multiple, twice a day oral doses of 100 mg to healthy subjects was 6.76 &micro;g/ml. Following administration of multiple doses of 50 mg and 100 mg of topiramate twice a day, the mean plasma elimination half-life was approximately 21 hours.</p><p>&nbsp;</p><p>Use with other AEDs</p><p>&nbsp;</p><p>Concomitant multiple-dose administration of topiramate, 100 to 400 mg twice a day, with phenytoin or carbamazepine shows dose proportional increases in plasma concentrations of topiramate.</p><p>&nbsp;</p><p>Renal impairment</p><p>&nbsp;</p><p>The plasma and renal clearance of topiramate are decreased in patients with moderate and severe impaired renal function (CL<sub>CR</sub> &le; 70 ml/min). As a result, higher steady-state topiramate plasma concentrations are expected for a given dose in renal-impaired patients as compared to those with normal renal function. In addition, patients with renal impairment will require a longer time to reach steady-state at each dose. In patients with moderate and severe renal impairment, half of the usual starting and maintenance dose is recommended.</p><p>&nbsp;</p><p>Topiramate is effectively removed from plasma by haemodialysis. A prolonged period of hemodialysis may cause topiramate concentration to fall below levels that are required to maintain an anti-seizure effect. To avoid rapid drops in topiramate plasma concentration during hemodialysis, a supplemental dose of topiramate may be required. The actual adjustment should take into account 1) the duration of dialysis period, 2) the clearance rate of the dialysis system being used, and 3) the effective renal clearance of topiramate in the patient being dialyzed.</p><p>&nbsp;</p><p>Hepatic impairment</p><p>&nbsp;</p><p>Plasma clearance of topiramate decreased a mean of 26% in patients with moderate to severe hepatic impairment. Therefore, topiramate should be administered with caution in patients with hepatic impairment.</p><p>&nbsp;</p><p>Elderly population</p><p>&nbsp;</p><p>Plasma clearance of topiramate is unchanged in elderly subjects in the absence of underlying renal disease.</p><p>&nbsp;</p><p>Paediatric population (pharmacokinetics, up to 12 years of age)</p><p>&nbsp;</p><p>The pharmacokinetics of topiramate in children, as in adults receiving add-on therapy, are linear, with clearance independent of dose and steady-state plasma concentrations increasing in proportion to dose. Children, however, have a higher clearance and a shorter elimination half-life. Consequently, the plasma concentrations of topiramate for the same mg/kg dose may be lower in children compared to adults. As in adults, hepatic enzyme inducing AEDs decrease the steady-state plasma concentrations.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In nonclinical studies of fertility, despite maternal and paternal toxicity as low as 8 mg/kg/day, no effects on fertility were observed, in male or female rats with doses up to 100 mg/kg/day.</p><p>&nbsp;</p><p>In preclinical studies, topiramate has been shown to have teratogenic effects in the species studied</p><p>(mice, rats and rabbits). In mice, fetal weights and skeletal ossification were reduced at</p><p>500 mg/kg/day in conjunction with maternal toxicity. Overall numbers of fetal malformations in mice were increased for all drug-treated groups (20, 100 and 500 mg/kg/day).</p><p>&nbsp;</p><p>In rats, dosage-related maternal and embryo/fetal toxicity (reduced fetal weights and/or skeletal ossification) were observed down to 20 mg/kg/day with teratogenic effects (limb and digit defects) at</p><p>400 mg/kg/day and above. In rabbits, dosage-related maternal toxicity was noted down to</p><p>10 mg/kg/day with embryo/fetal toxicity (increased lethality) down to 35 mg/kg/day, and teratogenic effects (rib and vertebral malformations) at 120 mg/kg/day.</p><p>&nbsp;</p><p>The teratogenic effects seen in rats and rabbits were similar to those seen with carbonic anhydrase inhibitors, which have not been associated with malformations in humans. Effects on growth were also indicated by lower weights at birth and during lactation for pups from female rats treated with 20 or 100 mg/kg/day during gestation and lactation. In rats, topiramate crosses the placental barrier.</p><p>&nbsp;</p><p>In juvenile rats, daily oral administration of topiramate at doses up to 300 mg/kg/day during the period of development corresponding to infancy, childhood, and adolescence resulted in toxicities similar to those in adult animals (decreased food consumption with decreased body weight gain, centrolobullar hepatocellular hypertrophy). There were no relevant effects on long bone (tibia) growth or bone (femur) mineral density, preweaning and reproductive development, neurological development (including assessments on memory and learning), mating and fertility or hysterotomy parameters.</p><p>&nbsp;</p><p>In a battery of <em>in vitro </em>and <em>in vivo</em> mutagenicity assays, topiramate did not show genotoxic potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sugar spheres (maize starch, sucrose), Povidone, Cellulose acetate</p><p>&nbsp;</p><p><u>Capsule</u></p><p>&nbsp;</p><p>Gelatine, Titanium dioxide (E171)</p><p>&nbsp;</p><p>Printing ink</p><p>&nbsp;</p><p>Black ink (iron oxide black (E172), shellac and propylene glycol).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C. Keep the bottle tightly closed to protect from moisture.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Opaque plastic bottle of HDPE with tamper-evident closure containing 20, 28, 60 or 100 capsules with granules.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Janssen Cilag AG, Switzerland 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October-2015  
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>